ARTICLE | Clinical News

Abraxane nab-paclitaxel regulatory update

November 17, 2014 8:00 AM UTC

Specialised Therapeutics Australia Pty. Ltd. (Melbourne, Australia) said Abraxane nab-paclitaxel is listed for reimbursement on the Australian Pharmaceutical Benefits Scheme (PBS) to treat pancreatic cancer. The albumin stabilized nanoparticle formulation of paclitaxel is approved for the indication in the U.S., EU and Australia. The U.K.'s NICE issued draft guidance recommending against the use of Abraxane for the indication in September (see BioCentury, Sept. 15). Abraxane is approved in more than 40 countries, including the U.S. and EU, as second-line treatment of metastatic breast cancer. The product is also approved in the U.S., Argentina, Australia, Japan and New Zealand for first-line treatment of advanced non-small cell lung cancer (NSCLC). ...